Last edition
News about Clinical Trials
J&J Reports 74% One-Year Disease-Free Survival with INLEXZO in High-Risk NMIBC
Johnson & Johnson reported strong new data from Cohort 4 of the SunRISe-1 study, showing that INLEXZO (gemcitabine intravesical system) achieved a 74 percent one-year disease-free survival rate in patients with BCG-unresponsive, high-risk papillary-only NMIBC, with over 95 percent progression-free and more than 92 percent avoiding bladder removal.
Clinical Trials | 06/12/2025 | By Dineshwori
ALS Association Announces USD 2M Support for Emerging ALS Treatments
The ALS Association has awarded $2 million through its Hoffman ALS Clinical Trial Awards Program to advance two early-stage therapeutic candidates, supporting efforts to accelerate the development of new treatments for the disease.
Clinical Trials | 06/12/2025 | By Dineshwori
Immorta Bio Reports Tumour Reduction Across Multiple Cancer Models with SenoVax
Immorta Bio has reported promising pre-clinical results showing that its anti-aging vaccine, SenoVax, reduced tumours across multiple validated cancer models. Developed in collaboration with academic institutions, the platform aims to dismantle tumour defense mechanisms and offer a non-toxic, longevity-driven approach to cancer treatment.
Clinical Trials | 05/12/2025 | By Dineshwori
Ascletis Advances First Oral Triple Agonist ASC37 to Clinical Development
Ascletis has selected ASC37—its first oral GLP-1R/GIPR/GCGR triple peptide agonist—for clinical development. Using the company’s POTENT technology, ASC37 showed markedly higher oral bioavailability and drug exposure than leading agents in non-human primate studies.
Clinical Trials | 01/12/2025 | By Dineshwori
New Innovation Hub to Make Maharashtra a Global Pharma & Biotech Hub
The government of Maharashtra plans to establish a state-of-the-art Life Sciences Innovation and Incubation Centre aimed at boosting research and development in pharmaceuticals, biotechnology, medical devices, diagnostics and digital health.
Clinical Trials | 29/11/2025 | By Darshana
Pin Therapeutics Administers First Dose of PIN-5018 in Adenoid Cystic Carcinoma Patient
Pin Therapeutics, a clinical-stage biotechnology company focused on targeted protein degradation, has begun dosing in a Phase 1 clinical trial evaluating its CK1α-selective degrader, PIN-5018. The first patient enrolled in the study has adenoid cystic carcinoma (ACC), a rare malignancy with limited treatment options.
Clinical Trials | 24/11/2025 | By Dineshwori
US FDA Approves PADCEV plus Keytruda for Certain Patients with Bladder Cancer
PADCEV plus Keytruda is the first and only approved perioperative treatment regimen that can improve survival over current standard of care (surgery alone) in cisplatin-ineligible patients with Muscle-Invasive Bladder Cancer (MIBC).
Clinical Trials | 24/11/2025 | By Dineshwori
Xenetic Biosciences has extended its research collaboration with the laboratory of Dr Alexey Stepanov, Institute Investigator at Scripps Research to advance the company’s R&D programme, evaluating the combined use of systemic DNase I and CAR T-cell therapies for difficult-to-treat cancers.
Clinical Trials | 20/11/2025 | By Dineshwori
Accession Therapeutics Doses First Patient in Phase 1 Trial of TROCEPT-01
Accession Therapeutics has dosed the first patient in its Phase 1 trial of TROCEPT-01 (ATTR-01), a first-in-class tumour-activated viral immunotherapy. Designed for systemic delivery, the therapy aims to selectively generate a checkpoint inhibitor within tumours, offering a targeted approach to cancer treatment.
Clinical Trials | 18/11/2025 | By Dineshwori
Vanda's Tradipitant Shows Strong Efficacy in Preventing Wegovy-Induced Nausea and Vomiting
Vanda Pharmaceuticals has announced positive topline results from its randomised controlled study evaluating tradipitant, an oral neurokinin-1 (NK-1) receptor antagonist, for preventing nausea and vomiting associated with GLP-1 receptor agonist Wegovy in overweight and obese adults.
Clinical Trials | 18/11/2025 | By Dineshwori | 125
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy